Biomarker Bonanza?

被引：5

作者：

Califf, Robert M. ^{[1
]}

Shah, Svati H. ^{[2
]}

Newby, L. Kristin ^{[2
]}

机构：

[1] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC 27710 USA

[2] Duke Clin Res Inst, Durham, NC USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2010年 / 55卷 / 12期

关键词：

biomarkers; biological markers; surrogate end point; acute coronary syndrome; ranolazine; brain natriuretic peptide; B-type natriuretic peptide; SURROGATE END-POINTS;

D O I：

10.1016/j.jacc.2009.10.051

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1197 / 1199

页数：3

共 8 条

[1] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[2]

CALIFF RM, 2008, DIFFUSION USE GENOMI

[3] Surrogate end points in clinical trials: Are we being misled? [J].

Fleming, TR ;

DeMets, DL .

ANNALS OF INTERNAL MEDICINE, 1996, 125 (07) :605-613

[4] Prospects for personalized cardiovascular medicine - The impact of genomics [J].

Ginsburg, GS ;

Donahue, MP ;

Newby, LK .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (09) :1615-1627

[5]

Hlatky Mark A, 2009, Circulation, V119, P2408, DOI 10.1161/CIRCULATIONAHA.109.192278

[6] B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Observations From the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) Trial [J].

Morrow, David A. ;

Scirica, Benjamin M. ;

Sabatine, Marc S. ;

de Lemos, James A. ;

Murphy, Sabina A. ;

Jarolim, Petr ;

Theroux, Pierre ;

Bode, Christophe ;

Braunwald, Eugene .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (12) :1189-1196

[7] Biomarkers and Cardiovascular Disease Determining Causality and Quantifying Contribution to Risk Assessment [J].

Shah, Svati H. ;

de Lemos, James A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (01) :92-93

[8] Chutes and Ladders on the Critical Path: Comparative Effectiveness, Product Value, and the Use of Biomarkers in Drug Development [J].

Woodcock, J. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) :12-14

← 1 →